[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]

Ken Takase, Toshihiro Miyamoto

Research output: Contribution to journalArticle

Abstract

In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Volume73
Issue number1
Publication statusPublished - Jan 1 2015

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Thalidomide
Therapeutics
Transplants
Survival
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]. / Takase, Ken; Miyamoto, Toshihiro.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 73, No. 1, 01.01.2015, p. 107-113.

Research output: Contribution to journalArticle

@article{0bb65db0c23d4b34a44c428fdabe9b41,
title = "[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]",
abstract = "In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.",
author = "Ken Takase and Toshihiro Miyamoto",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "73",
pages = "107--113",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - [Allogeneic hematopoietic stem cell transplantation for multiple myeloma]

AU - Takase, Ken

AU - Miyamoto, Toshihiro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.

AB - In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.

UR - http://www.scopus.com/inward/record.url?scp=84925231603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925231603&partnerID=8YFLogxK

M3 - Article

C2 - 25626314

AN - SCOPUS:84925231603

VL - 73

SP - 107

EP - 113

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 1

ER -